Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection - PubMed (original) (raw)
. 2005 Nov 1;106(9):2995-3003.
doi: 10.1182/blood-2004-12-4906. Epub 2005 Jul 19.
Affiliations
- PMID: 16030195
- DOI: 10.1182/blood-2004-12-4906
Free article
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection
Maria Moeller et al. Blood. 2005.
Free article
Abstract
Because CD4+ T cells play a key role in aiding cellular immune responses, we wanted to assess whether increasing numbers of gene-engineered antigen-restricted CD4+ T cells could enhance an antitumor response mediated by similarly gene-engineered CD8+ T cells. In this study, we have used retroviral transduction to generate erbB2-reactive mouse T-cell populations composed of various proportions of CD4+ and CD8+ cells and then determined the antitumor reactivity of these mixtures. Gene-modified CD4+ and CD8+ T cells were shown to specifically secrete Tc1 (T cytotoxic-1) or Tc2 cytokines, proliferate, and lyse erbB2+ tumor targets following antigen ligation in vitro. In adoptive transfer experiments using severe combined immunodeficient (scid) mice, we demonstrated that injection of equivalent numbers of antigen-specific engineered CD8+ and CD4+ T cells led to significant improvement in survival of mice bearing established lung metastases compared with transfer of unfractionated (largely CD8+) engineered T cells. Transferred CD4+ T cells had to be antigen-specific (not just activated) and secrete interferon gamma (IFN-gamma) to potentiate the antitumor effect. Importantly, antitumor responses in these mice correlated with localization and persistence of gene-engineered T cells at the tumor site. Strikingly, mice that survived primary tumor challenge could reject a subsequent rechallenge. Overall, this study has highlighted the therapeutic potential of using combined transfer of antigen-specific gene-modified CD8+ and CD4+ T cells to significantly enhance T-cell adoptive transfer strategies for cancer therapy.
Similar articles
- Sustained antigen-specific antitumor recall response mediated by gene-modified CD4+ T helper-1 and CD8+ T cells.
Moeller M, Kershaw MH, Cameron R, Westwood JA, Trapani JA, Smyth MJ, Darcy PK. Moeller M, et al. Cancer Res. 2007 Dec 1;67(23):11428-37. doi: 10.1158/0008-5472.CAN-07-1141. Cancer Res. 2007. PMID: 18056471 - Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ, Reome JB, Hollenbaugh JA, Dutton RW. Dobrzanski MJ, et al. J Immunol. 2004 Feb 1;172(3):1380-90. doi: 10.4049/jimmunol.172.3.1380. J Immunol. 2004. PMID: 14734713 - IL-4-transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lymphocytes that cure lung metastases upon adoptive transfer.
Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. Rodolfo M, et al. J Immunol. 1999 Aug 15;163(4):1923-8. J Immunol. 1999. PMID: 10438927 - Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy.
Renaude E, Kroemer M, Borg C, Peixoto P, Hervouet E, Loyon R, Adotévi O. Renaude E, et al. Front Immunol. 2021 Jun 28;12:669992. doi: 10.3389/fimmu.2021.669992. eCollection 2021. Front Immunol. 2021. PMID: 34262562 Free PMC article. Review. - Engineering CD4+ T Cells to Enhance Cancer Immunity.
Sillito F, Holler A, Stauss HJ. Sillito F, et al. Cells. 2020 Jul 18;9(7):1721. doi: 10.3390/cells9071721. Cells. 2020. PMID: 32708397 Free PMC article. Review.
Cited by
- Key role of CD4+ T cells in determining CD8 function during CAR-T cell manufacture.
Melenhorst JJ, Oliveira BC. Melenhorst JJ, et al. J Immunother Cancer. 2024 Mar 13;12(3):e008723. doi: 10.1136/jitc-2023-008723. J Immunother Cancer. 2024. PMID: 38485191 Free PMC article. No abstract available. - CD8+ chimeric antigen receptor T cells manufactured in absence of CD4+ cells exhibit hypofunctional phenotype.
Lee SY, Lee DH, Sun W, Cervantes-Contreras F, Basom RS, Wu F, Liu S, Rai R, Mirzaei HR, O'Steen S, Green DJ, Shadman M, Till BG. Lee SY, et al. J Immunother Cancer. 2023 Nov 20;11(11):e007803. doi: 10.1136/jitc-2023-007803. J Immunother Cancer. 2023. PMID: 38251688 Free PMC article. - The Role of CD4 T Cell Help in CD8 T Cell Differentiation and Function During Chronic Infection and Cancer.
Topchyan P, Lin S, Cui W. Topchyan P, et al. Immune Netw. 2023 Oct 23;23(5):e41. doi: 10.4110/in.2023.23.e41. eCollection 2023 Oct. Immune Netw. 2023. PMID: 37970230 Free PMC article. Review. - Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.
Bandara V, Foeng J, Gundsambuu B, Norton TS, Napoli S, McPeake DJ, Tyllis TS, Rohani-Rad E, Abbott C, Mills SJ, Tan LY, Thompson EJ, Willet VM, Nikitaras VJ, Zheng J, Comerford I, Johnson A, Coombs J, Oehler MK, Ricciardelli C, Cowin AJ, Bonder CS, Jensen M, Sadlon TJ, McColl SR, Barry SC. Bandara V, et al. Nat Commun. 2023 Sep 8;14(1):5546. doi: 10.1038/s41467-023-41338-y. Nat Commun. 2023. PMID: 37684239 Free PMC article. - Rapid generation of genetically engineered T cells for the treatment of virus-related cancers.
Jiang J, Xia M, Zhang L, Chen X, Zhao Y, Zeng C, Yang H, Liang P, Li G, Li N, Qi H, Wei T, Ren L. Jiang J, et al. Cancer Sci. 2022 Nov;113(11):3686-3697. doi: 10.1111/cas.15528. Epub 2022 Sep 9. Cancer Sci. 2022. PMID: 35950597 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous